PepGen (PEPG) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
PepGen (PEPG) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, losing 46.8% versus a loss of 52.9%. ProQR Therapeutics N.V. is the larger company by market cap ($184.9 million vs $179.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEPG | PRQR |
|---|---|---|
| Share price | $2.60 | $1.31 |
| Market cap | $179.84M | $184.87M |
| 1-day change | +2.77% | -9.66% |
| YTD return | -60.06% | -35.15% |
| 1-year return | -46.83% | -52.88% |
| 5-year return | — | -82.37% |
| EPS (TTM) | $-1.01 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-89.66M | — |
| 52-week high | $7.80 | $3.10 |
| 52-week low | $1.31 | $1.30 |
| Distance from 52-week high | -66.67% | -57.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +291.92% | +493.89% |
| Average volume | 864.38K | 832.21K |
| Shares outstanding | 69.17M | 141.12M |
| Employees | 57 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
PEPG vs PRQR FAQ
Which is bigger, PepGen or ProQR Therapeutics N.V.?
ProQR Therapeutics N.V. (PRQR) is larger, with a market capitalization of $184.87M compared with $179.84M for PepGen (PEPG).
Which stock has performed better over the past year, PEPG or PRQR?
PEPG returned -46.83% over the past 12 months, compared with -52.88% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are PepGen and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.